Sean E Collins
Overview
Explore the profile of Sean E Collins including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Selzer L, VanderVeen L, Parvangada A, Martin R, Collins S, Mehrotra M, et al.
J Acquir Immune Defic Syndr
. 2024 Sep;
98(1):64-71.
PMID: 39298557
Background: HIV envelope (env) diversity may result in resistance to broadly neutralizing antibodies (bNAbs). Assessment of genotypic or phenotypic susceptibility to antiretroviral treatment is often performed in people with HIV-1...
2.
Eron J, Little S, Crofoot G, Cook P, Ruane P, Jayaweera D, et al.
Lancet HIV
. 2024 Feb;
11(3):e146-e155.
PMID: 38307098
Background: Long-acting treatment for HIV has potential to improve adherence, provide durable viral suppression, and have long-term individual and public health benefits. We evaluated treatment with two antibodies that broadly...
3.
Sax P, Andreatta K, Molina J, Daar E, Hagins D, Acosta R, et al.
AIDS
. 2022 Apr;
36(11):1511-1520.
PMID: 35466963
Objective: We investigated the prevalence of preexisting M184V/I and associated risk factors among clinical trial participants with suppressed HIV and evaluated the impact of M184V/I on virologic response after switching...
4.
Moldt B, Gunthard H, Workowski K, Little S, Eron J, Overton E, et al.
AIDS
. 2021 Sep;
36(2):205-214.
PMID: 34586088
Objective: Persistence of the viral reservoir is the main barrier to curing HIV. Initiation of ART during acute HIV infection can limit the size and diversity of the reservoir. In...
5.
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, et al.
J Acquir Immune Defic Syndr
. 2021 Sep;
88(4):393-398.
PMID: 34506342
Background: We characterized the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a broad population of pediatric/adolescent/adult/elderly females living with HIV (FWH). Setting: Integrated analysis. Methods: Available data from 5...
6.
Hagins D, Kumar P, Saag M, Wurapa A, Brar I, Berger D, et al.
J Acquir Immune Defic Syndr
. 2021 Aug;
88(1):86-95.
PMID: 34397746
Background: With the highest rates of HIV/AIDS in the United States, Black Americans are still underrepresented in HIV medical research. Setting: BRAAVE (NCT03631732) is a randomized, phase 3b, multicenter, open-label...
7.
Moldt B, Parvangada A, Martin R, Pace C, Balakrishnan M, Thomsen N, et al.
J Acquir Immune Defic Syndr
. 2021 Aug;
88(1):61-69.
PMID: 34397744
Background: HIV envelope (env) diversity represents a significant challenge for the use of broadly neutralizing antibodies (bNAbs) in HIV treatment and cure studies. Screening for viral sensitivity to bNAbs to...
8.
Joseph Y, Yao Z, Dua A, Severe P, Collins S, Bang H, et al.
J Int AIDS Soc
. 2021 Jul;
24(7):e25721.
PMID: 34235862
Introduction: Long-term mortality among TB survivors appears to be higher than control populations without TB in many settings. However, data are limited among persons with HIV (PWH). We assessed the...
9.
Acosta R, Chen G, Chang S, Martin R, Wang X, Huang H, et al.
J Antimicrob Chemother
. 2021 Apr;
76(8):2153-2157.
PMID: 33880558
Objectives: Two Phase 3, randomized, double-blind, active-controlled studies of initial HIV-1 treatment demonstrated that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC; Study 1489) or to DTG+F/TAF (Study 1490) through...
10.
Mayer K, Molina J, Thompson M, Anderson P, Mounzer K, De Wet J, et al.
Lancet
. 2020 Jul;
396(10246):239-254.
PMID: 32711800
Background: Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we report primary results from a...